Wall Street Zen Upgrades Septerna (NASDAQ:SEPN) to “Strong-Buy”

Septerna (NASDAQ:SEPN) was upgraded by stock analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday.

SEPN has been the subject of several other research reports. Truist Financial started coverage on shares of Septerna in a research report on Monday. They issued a “buy” rating and a $34.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 target price on shares of Septerna in a research note on Friday, September 5th. Raymond James Financial began coverage on shares of Septerna in a research note on Friday. They set a “strong-buy” rating and a $38.00 price target on the stock. Wells Fargo & Company upgraded shares of Septerna from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $18.00 to $28.00 in a report on Friday, November 14th. Finally, HC Wainwright upped their price objective on shares of Septerna from $26.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $31.00.

Septerna Price Performance

NASDAQ:SEPN opened at $29.58 on Friday. The business’s 50-day moving average is $23.76 and its two-hundred day moving average is $16.87. The firm has a market capitalization of $1.32 billion, a PE ratio of -19.59 and a beta of 3.80. Septerna has a 12 month low of $4.17 and a 12 month high of $30.50.

Septerna (NASDAQ:SEPN) last posted its earnings results on Monday, November 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). The company had revenue of $21.50 million during the quarter, compared to analyst estimates of $24.50 million. Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. Equities analysts anticipate that Septerna will post -7.11 EPS for the current year.

Insider Buying and Selling

In other Septerna news, SVP Daniel D. Long sold 3,501 shares of the firm’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $18.06, for a total transaction of $63,228.06. Following the completion of the transaction, the senior vice president directly owned 92,911 shares of the company’s stock, valued at $1,677,972.66. This trade represents a 3.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Septerna

Institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. acquired a new position in Septerna in the third quarter worth about $36,000. Covestor Ltd raised its stake in Septerna by 55.8% during the third quarter. Covestor Ltd now owns 3,620 shares of the company’s stock valued at $68,000 after buying an additional 1,296 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in Septerna by 88.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock worth $78,000 after buying an additional 1,945 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Septerna by 15.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after acquiring an additional 1,315 shares in the last quarter. Finally, Quadrature Capital Ltd acquired a new position in shares of Septerna in the 2nd quarter worth approximately $107,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.